Known safety concerns, contraindications, and risk factors.
No peer-reviewed studies have investigated the clinical safety of the TB-500 heptapeptide specifically in humans. Safety profiles are extrapolated from trials of the parent molecule Thymosin β4 or animal models. No Phase 3 RCTs exist. Exercise appropriate caution.
Active or Recent Malignancy
Strictly contraindicated due to pro-angiogenic mechanisms potentially supporting tumor growth and metastasis.
Pregnancy and Breastfeeding
Total absence of safety data regarding reproductive health and fetal development.
Competitive Athletes (WADA-Tested)
TB-500 is prohibited under WADA categories S0 (Non-Approved Substances) and S2 (Peptide Hormones and Growth Factors).
Severe Hepatic or Renal Impairment
No dosing or clearance guidelines exist for patients with organ impairment.
Anticoagulant or Antiplatelet Therapy
TB-500 may influence hemostasis and wound-healing dynamics. Caution with Warfarin and Aspirin.